Working… Menu

A Phase 3b Study of Vernakalant Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation (AF)(MK-6621-045) (ACT V)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00989001
Recruitment Status : Terminated
First Posted : October 2, 2009
Last Update Posted : March 10, 2014
Information provided by (Responsible Party):
Correvio International Sarl

Brief Summary:
The purpose of this study is to evaluate the safety and efficacy of vernakalant injection in subjects with recent onset (AF > 3 hours to <= 7 days), symptomatic atrial fibrillation and no evidence or history of congestive heart failure.

Condition or disease Intervention/treatment Phase
Atrial Fibrillation Drug: Vernakalant Drug: Placebo Phase 3

Detailed Description:
Participants received a 10-minute intravenous (IV) infusion of vernakalant (3 mg/kg) or an equivalent amount of normal saline (placebo), followed by a 15-minute observation period. If the participant was still in atrial fibrillation or atrial flutter, a second 10-minute IV infusion of vernakalant (2 mg/kg) or an equivalent amount of placebo was administered unless the participant experienced any dose-stopping criteria after the start of the first infusion. If a participant converted to sinus rhythm during the first or second infusion, that infusion was completed.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 217 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3b Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Vernakalant Hydrochloride Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation
Study Start Date : October 2009
Actual Primary Completion Date : November 2010
Actual Study Completion Date : November 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Vernakalant
Maximum volume of 100 mL as per the dosing schedule, administered intravenously (IV) over 10 minutes
Drug: Vernakalant
Maximum volume of 100 mL as per the dosing schedule, administered intravenously (IV) over 10 minutes
Other Name: RSD1235

Placebo Comparator: Placebo
Placebo (saline) administered IV at same volume and rate as per dosing schedule for vernakalant
Drug: Placebo

Primary Outcome Measures :
  1. Number of Participants who Experience Hypotension, Ventricular Arrhythmias and/or Death [ Time Frame: Occurring within the first two hours after start of study treatment ]
    Hypotension defined as: systolic blood pressure (SBP) <90 mmHg and treated with pressors; SBP <90 mmHg and treated with albumin, dextran or hydroxyethyl starch; or SBP <90 mmHg and seizures. Ventricular arrhythmias defined as: Sustained ventricular tachycardia with a heart rate of >120 beats per minute. Sustained tachycardia defined as lasting >30 seconds; Torsade de Pointes with a duration of >10 seconds; Ventricular fibrillation of any duration.

  2. Number of Participant with Successful Conversion to Sinus rhythm (SR) [ Time Frame: Occurring within 90 minutes of first exposure to study treatment ]
    Successful conversion defined as return to sinus rhythm for at least 1 minute documented by Holter electrocardiogram (ECG) or by two consecutive 12-lead ECGs recorded > 1 minute apart within 90 minutes of first exposure to study treatment

Secondary Outcome Measures :
  1. Time from First Exposure to Study Treatment to Conversion of AF to SR [ Time Frame: Occurring within 90 minutes after study treatment ]
  2. Number of Participants who Report No Symptoms [ Time Frame: Occurring 90 minutes after first exposure to study treatment ]
    Participant was considered a success (no symptoms) if they did not have any of the following symptoms at 90 minutes: palpitations, dyspnea, dizziness, chest pain or fatigue

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Females must be not pregnant or nursing and if pre-menopausal, must be using an effective form of birth control from time of screening until 30 days post study treatment
  • Subject must have recent onset (> 3 hours to <= 7 days) symptomatic AF to be best managed by acute conversion to SR
  • Subject must have adequate anticoagulant therapy
  • Subject must have systolic blood pressure (SBP) above 90 mmHg and less than 160 mmHg and diastolic blood pressure (DBP) less than 95 mmHg at screening and baseline
  • Subject must have a body weight between 45 and 136 kg, inclusive (99 and 300 lbs)

Exclusion Criteria:

  • Subject has a history of heart failure or documentation of left ventricular dysfunction
  • Subject has known or suspected prolonged QT or uncorrected QT interval of > 0.440 sec
  • Subject has symptomatic bradycardia or ventricular rate less than 50 bpm at Screening, unless controlled by a pacemaker
  • Subject has bradycardia (heart rate less than 50 bpm) or hypotension (SBP less that 90 mmHg) after receiving a loading, bolus dose, or sustained infusion of any rate control medication during Screening
  • Subject has a QRS interval > 0.14 sec., unless subject has a pacemaker
  • Subject had a myocardial infarction (MI), acute coronary syndrome, cardiac surgery (including percutaneous transluminal coronary angioplasty (PTCA) or stent placement), within 30 days prior to enrollment or subject has evidence of new ischemic changes on Screening 12-lead ECG
  • Subject has troponin I or T levels beyond the upper limit of normal for the local lab
  • Subject has significant valvular stenosis, hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy or constrictive pericarditis
  • Subject has failed electrical cardioversion for AF at anytime
  • Subject has failed pharmacologic conversion with an intravenous Class I or Class III antiarrhythmic drug for this episode of AF
  • Subject has any known reversible causes of AF such as alcohol intoxication, pulmonary embolism, hyperthyroidism, acute pericarditis or hypoxemia
  • Subject has uncorrected electrolyte imbalance
  • Subject has clinical evidence of digoxin toxicity
  • Subject has a history of clinically significant illness (e.g. neurological, gastrointestinal, renal, hepatic, pulmonary, metabolic, endocrine, hematological, or psychiatric), medical condition or laboratory abnormality within 4 weeks prior to Screening
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Correvio International Sarl Identifier: NCT00989001    
Other Study ID Numbers: 6621-045
6517-CL-0020 ( Other Identifier: Merck )
First Posted: October 2, 2009    Key Record Dates
Last Update Posted: March 10, 2014
Last Verified: February 2014
Keywords provided by Correvio International Sarl:
Atrial Fibrillation
Additional relevant MeSH terms:
Layout table for MeSH terms
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes